Skip to search formSkip to main contentSkip to account menu

piroximone

Known as: 4-ethyl-1,3-dihydro-5-(4-pyridinylcarbonyl)-2H-imidazol-2-one 
National Institutes of Health

Related topics

Related topics

5 relations

Broader (4)

Cardiotonic AgentsImidazolesPhosphodiesterase InhibitorsPlatelet Aggregation Inhibitors

Narrower (1)

MDL 19,205

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
1993
1993
Circulatory effects of the PDE-inhibitors piroximone and enoximone.
1. The isolated circulatory response to intravenous application of the phosphodiesterase (PDE) inhibitors piroximone and… 
1991
1991
Type III phosphodiesterase plays a necessary role in the growth-promoting actions of insulin, insulin-like growth factor-I, and Ha p21ras in Xenopus laevis oocytes.
Three phosphodiesterase (PDE) type III inhibitors were tested and found to inhibit Xenopus oocyte maturation induced by insulin… 
1991
1991
Effects of a standardized meal on the pharmacokinetics of the new cardiotonic agent piroximone.
The influence of food on the pharmacokinetics of piroximone (MDL 19.205, CAS 84490-12-0) was evaluated in two groups of 6 healthy… 
Review
1990
Review
1990
Pharmacokinetics and pharmacodynamics of phosphodiesterase-III inhibitors
Review
1989
Review
1989
Biochemical aspects of inhibition of cardiovascular low (Km) cyclic adenosine monophosphate phosphodiesterase.
1989
1989
Subcellular distribution of high-affinity type IV cyclic AMP phosphodiesterase activities in rabbit ventricular myocardium: relations to post-natal maturation.
Highly Cited
1988
Highly Cited
1988
Do positive inotropic agents adversely affect the survival of patients with chronic congestive heart failure? I. Introduction.
1987
1987
Effects of Long‐Term Therapy with Oral Piroximone on Resting Hemodynamics, Peak Aerobic Capacity, and the Anaerobic Threshold in Patients with Heart Failure
Summary Piroximone (MDL 19205), a new imidazole derivative with positive inotropic and vasodilating properties, was administered… 
1986
1986
Persistent hemodynamic effects without long-term clinical benefits in response to oral piroximone (MDL 19,205) in patients with congestive heart failure.
Piroximone (MDL 19,205), a new phosphodiesterase inhibitor with positive inotropic and vasodilating properties, was administered… 
1986
1986
Acute Hemodynamic Effects of Piroximone (MDL 19,205) in Patients with Moderate Congestive Heart Failure: Comparison with Sodium Nitroprusside
Summary: Piroximone (MDL 19,205), a new imidazolone derivative, was given intravenously to 14 patients with congestive heart… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)